COPENHAGEN/LONDON (Reuters): Novo Nordisk is taking the launch of its obesity drug Wegovy “a little slower than planned” in new markets due to higher than expected demand in the three countries where it is currently sold, an executive said on Tuesday.
Camilla Sylvest, executive vice president of commercial strategy and corporate affairs, made the comment during a news conference.
A weekly injection of Wegovy, which was launched in the US in June 2021, leads to an average weight loss of around 15 per cent, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities.
Jalil Afridi Washington DC: The Deputy Spokesperson of Pentagon, Sabrina Singh said that “I do…
THE HAGUE: South Africa has urged the top UN court to order a halt to…
WASHINGTON (AFP): US President Joe Biden is trying to shore up his support among vital…
OTTAWA (Reuters) : Canada on Thursday imposed sanctions on four Israeli individuals accused of violence…
MADINAH AL-MUNAWWARAH (INP): Minister for Religious Affairs and Interfaith Harmony Chaudhry Salik Hussain on Thursday…
F.P. Report LAHORE: Chairman Joint Chiefs of Staff Committee General Sahir Shamshad Mirza, addressed the…
This website uses cookies.